GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Cost of Goods Sold

CARsgen Therapeutics Holdings (HKSE:02171) Cost of Goods Sold : HK$5.08 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings Cost of Goods Sold?

CARsgen Therapeutics Holdings's cost of goods sold for the six months ended in Jun. 2024 was HK$5.08 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2024 was HK$5.08 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CARsgen Therapeutics Holdings's Gross Margin % for the six months ended in Jun. 2024 was 25.51%.

Cost of Goods Sold is also directly linked to Inventory Turnover. CARsgen Therapeutics Holdings's Inventory Turnover for the six months ended in Jun. 2024 was 1.64.


CARsgen Therapeutics Holdings Cost of Goods Sold Historical Data

The historical data trend for CARsgen Therapeutics Holdings's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings Cost of Goods Sold Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
- - - - -

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 5.08

CARsgen Therapeutics Holdings Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$5.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CARsgen Therapeutics Holdings  (HKSE:02171) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CARsgen Therapeutics Holdings's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(6.825 - 5.084) / 6.825
=25.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

CARsgen Therapeutics Holdings's Inventory Turnover for the six months ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


CARsgen Therapeutics Holdings Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Candock Holdings Limited 2501 Other
Yang Xuehong 2501 Other
Quan Zhou Shi Ding Wo Chuang Feng Tou Zi Zhong Xin You Xian He Huo 2501 Other
Yi De Kong Gu You Xian Gong Si 2501 Other
Yi Jie Sheng Wu Ji Shu Kong Gu You Xian Gong Si 2501 Other
Accure Biotech Limited 2501 Other
Wang Huamao 2401 A concert party to an agreement to buy shares
Li Zonghai 2401 A concert party to an agreement to buy shares
Guo Huaqing 2101 Beneficial owner
Guo Bingsen 2401 A concert party to an agreement to buy shares
Redelle Holding Limited 2501 Other
He Xi Holdings Limited 2501 Other
Guo Xiaojing 2501 Other
Chen Haiou 2501 Other
Cart Biotech Limited 2501 Other

CARsgen Therapeutics Holdings Headlines

No Headlines